The post hoc analysis from the pivotal Phase III IRIDIUM study—presented virtually at the European Respiratory Society (ERS) International Congress 2020— also showed the safety profile for high-dose
Alkahest is a clinical stage company that is focussed on the discovery and development of treatments for neurodegenerative and age-related diseases with therapies that target the aging plasma
PANS is a condition defined by sudden onset of obsessive-compulsive symptoms and/or severe eating restrictions, along with at least two other cognitive, behavioral, or neurological symptoms, according to
PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, commented, “Submitting this IND is the most important milestone the Company has met thus far in the clinical development of our
SCLC is a highly aggressive, fast-growing form of lung cancer that typically recurs and progresses rapidly despite initial response to chemotherapy.1,2 The approval by the European Commission was
JTX-1811, which is a monoclonal antibody, is said to have been designed by Jounce Therapeutics to preferentially deplete immunosuppressive tumour-infiltrating T regulatory (TITR) cells. The immunotherapy candidate’s target
OMS906 is the company’s lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3), the key activator of the complement system’s alternative pathway. FDA’s clearance of the IND
VIR-7831 is a fully human anti-SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus-2) monoclonal antibody that is being developed for the early treatment of the viral disease in patients who
The results were consistent in patients both with and without type 2 diabetes (T2D). CKD is a serious, progressive condition defined by decreased kidney function affecting nearly 700
In this connection, the Canadian pharma company has submitted an investigational new drug (IND) application for FSD201 with the US regulator. The phase 2 trial will be a
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.